ABSTRACT
Objectives To evaluate the efficacy of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL) and the relationship of clinical prognosis with the International Prognostic Index (IPI) by the using rituximab in autologous peripheral stem cell transplantation (APBSCT) for the patients of DLBCL. Methods 21 patients with DLBCL, 11 patients of them were at IPI low risk, and 3 patients were IPI at low intermediate risk, 3 patients were at IPI high intermediate risk, 4patients IPI high risk. Rituximab combined with CHOP regimen (cyclophosphamide, adriamycin, vincfistine and prednisone) was given for 4～8 courses. 5 patients received APBSCT. The mobilizing regimen was rituximab combined with cyclophosphamide(CTX) and etoposide(VP16). The conditioning regimen were CBV(CTX combined with VP16 and carmustine). Results In 21 patients, the complete response rate was 61.9 %,with overall response rate 90.5 %. 2-year progression free survival was (69.74±10.43)%. 2-year overall survival was (84.44:1:8.35) %. The complete response rate was 92.9 % and overall response rate was 100 % in the patients IPI≤2. The overall response rate was 71.4 % in the patients with IPI≥3. The complete response rate was higher in the patients with IPI≤ 2 (P＜0.01). The amount of mononuclear cells (M NC) in harvest were 7.34 (4.6～8.53)×108/kg. The CD+34 cells in harvest were 8.82 (2.1～10.34)×1O6/kg. The mean time of neutrephil recovering to 0.5×109/L after APBSCT was +9 day. The mean time of platelet recovering to 20×109/L after APBSCT was +12 day. The major adverse reaction were infusion related response (14.3 %) and hematological toxieities. Conclusion The efficacy of rituximab combined with chemotherapy in the treatment of DLBCL is effective, The complete response rate was higher in the patients with IPI≤2 than in the patients with IPI≥3.Using rituximab in mobilizing regimen, all patients had harvested enough CD+34 cells. Rituximab given at +1day did not affect the hematopoiesis reconstruction.
ABSTRACT
Objective To evaluate the acute side effects and efficacy of the intraluminal brachytherapy combined with external radiation and synchronous chemotherapy in the treatment of bronchial lung cancer.Methods From June 2001 to June 2003,42 patients with bronchial lung cancer were divided into treatment group and control group randomly.21 lung cancer patients with major airway obstruction were treated by combined intralumihal brachytherapy with external beam radiotherapy and synchronous chemotherapy.Results The overall response rate(CR+PR)in treatment group and control group were 85.7% and 57.1%(P＜0.05).There were no serious complication during the treatment except for irritant cough and leukocytopenia.Conclusion Intraluminal brachytherapy may result in symptom improvement in patients with major airway occlusion of lung cancer.The intraluminal bmchytherapy combined with external beam radiothempy and synchronous chemotherapy is an effective method in treatment of lung cancer.
ABSTRACT
Objective To study the curative effect and adverse drug reactions of lentinan combination with chemotherapy in the treatment of advanced gastric cancer.Methods 115 eases of advanced gastric cancer patients are divided to treatment group and control group randomly.57 pafients in control group ale treated with the chemotherapy rcglment:L-OHP combination with FT-207 and CF,58 patients in treatment group are treated with the chemotherapy regiment:L-OHP combination with FT-207 and CF,cooperating with the synthetical treatment with lenfinan and vitamin B12,folic acid and so on.Results The control group:there are 18 cases get PR,the total effective rate is 31.6%,TTP is 3.1 months,MST is 5.5 months,the rate of survival in first year and second years is 56.1%and 22.8% respectively.The treatment group:there are l case get CR and 29 cases get PR,the total effective rate is 51%,TTP is 4.5 months.MST iS 9.8 months,the rote of survival in first year and second years is 81.1%and 51.7%respectively.There is statistieall difference between these two groups(P＜0.05).The main adverse drug reactions of two groups are restraint of marrow and gastrointestinal reactions.there is statistical difiefence in the decrease of HbO2 and the rate of occurrence of buecal inflammation between these two groups.Conclusion The method of lentinan combination with chemotherapy in the synthetical treatment of advanced gastric cancer has high effective rate and small adverse drug reactions.It is worth of being popularized.
ABSTRACT
Objective To evaluate the efficacy and toxicity of combined pegylated liposomaldoxorubicin (PLD) and carboplatin in the treatment of patients with recurrent epithelial ovarian cancer.Methods We retrospectively reviewed 67 patients with recurrent epithelial ovarian cancer or primaryperitoneal adenocarcinoma (8 eases) who were treated with combined PLD and earboplatin. The responserate, survival and toxicity were evaluated. The mean age for 67 patients was 52.1 (39-76) years. All ofthem received eytoreductive surgery followed by platinum-based chemotherapy either with paclitaxel orcyclophosphamide and doxorubicin after diagnosis. Combined PLD and carboplatin was used as first orsecond-line treatment or even after multiple lines of treatment after disease recurred. Patients were treatedwith PLD at 35-40 mg/m2combined with carboplatin at an area under curve ( AUC ) of 5 once every 4weeks. Results Forty-nine. Patients were evaluable for response. Twenty-three (47%) patients had acomplete response, 13 (27%) had a partial response, 3 (6%) had stable disease and 10 (20%) hadprogressive disease. The estimated median progression-free survival (PFS) was 8 months. The 1-year and 2-year survival rates were 73% and 55%, respectively. All of the 67 patients were evaluated for toxicity. Thetreatment was terminated in 2 patients due to allergic-like infusion reaction. Four patients who had acuteinfusion reaction with shortness of breath and tightness of chest did not terminate the treatment because nosuch reaction occurred when restarted the infusion. There were 2 patients with G2and 3 patients with G3hand-foot syndrome, 2 patients had G4stomatitis, and 8 patients had G3leukopeni,, No G4leukopenia orcardiotoxicity eceurred. Conclusion The combination of PLD and carboplatin is an active and wellotolerated regimen in the treatment of patients with recurrent epithelial ovarian cancer.
ABSTRACT
Objective To evaluate the curative effect of chemotherapy combined with radiotherapy for limited-stage small cell lung cancer(LD-SCLC).Methods 34 cases of patients with LD-SCLC were rand- mized into interdigitating chemoradiotherapy group and sequential chemoradiotherapy group.All patients re- ceived four to six cycles of alternating CE(C:carboplatin 300 mg/m~2 d_1;E:etoposide100 mg d_(1～5)and CAP(C: cyclophosphamide 600 mg/m~2 d_(1,8);A:adriamycin 40 mg/m~2 d_1;P:cisplatin 50 mg d_(3～5)chemotherapy,three weeks for a cycle.All patients also received thoracic radiotherapy with conventional fraction,2.0 Gy per frac- tion,five fractions per week.The total dose was 60 Gy.Results In interdigitating chemoradiotherapy group, CR was 64.7%,PR was 29.4%,NR was 5.9% and PD was 0 after chemo-radiation therapy.In sequential chemoradiotherapy group,CR was 23.5%,PR was 52.9%,NR was 23.5% and PD was 0 after chemothera- py,and CR was 58.8%,PR was 35.3%,NR was 5.9% and PD was 0 after radiotherapy.Conclusion The therapeutic effect of chemotherapy combined with radiotherapy for LD-SCLC was satisying.There was no sig- nificant difference in the effect between the two groups.
ABSTRACT
Objective To evaluate the efficacy and safety of ESHAP regimen,as a salvage regimen, in treating patients with relapsed or refractory aggressive NHL.Methods 38 patients with relapsed or refrac- tory aggressive NHL were selected to be treated by ESHAP regimen.Results The 38 patients received ES- HAP regimen with a range of 2～6 cycles. The total RR was 55.3 % with complete response(CR)rate of 26.3 %.The major toxicity was myelosuppression with infection,which was tolerable.Conclusion ESHAP regimen is one of safe and effective salvage regimens for the patients with relapsed or refractory aggressive NHL.